1
|
Harvey DJ. ANALYSIS OF CARBOHYDRATES AND GLYCOCONJUGATES BY MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY: AN UPDATE FOR 2015-2016. MASS SPECTROMETRY REVIEWS 2021; 40:408-565. [PMID: 33725404 DOI: 10.1002/mas.21651] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 07/24/2020] [Indexed: 06/12/2023]
Abstract
This review is the ninth update of the original article published in 1999 on the application of matrix-assisted laser desorption/ionization (MALDI) mass spectrometry to the analysis of carbohydrates and glycoconjugates and brings coverage of the literature to the end of 2016. Also included are papers that describe methods appropriate to analysis by MALDI, such as sample preparation techniques, even though the ionization method is not MALDI. Topics covered in the first part of the review include general aspects such as theory of the MALDI process, matrices, derivatization, MALDI imaging, fragmentation and arrays. The second part of the review is devoted to applications to various structural types such as oligo- and poly-saccharides, glycoproteins, glycolipids, glycosides and biopharmaceuticals. Much of this material is presented in tabular form. The third part of the review covers medical and industrial applications of the technique, studies of enzyme reactions and applications to chemical synthesis. The reported work shows increasing use of combined new techniques such as ion mobility and the enormous impact that MALDI imaging is having. MALDI, although invented over 30 years ago is still an ideal technique for carbohydrate analysis and advancements in the technique and range of applications show no sign of deminishing. © 2020 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- David J Harvey
- Nuffield Department of Medicine, Target Discovery Institute, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom
| |
Collapse
|
2
|
Ng KS, Smith JA, McAteer MP, Mead BE, Ware J, Jackson FO, Carter A, Ferreira L, Bure K, Rowley JA, Reeve B, Brindley DA, Karp JM. Bioprocess decision support tool for scalable manufacture of extracellular vesicles. Biotechnol Bioeng 2019; 116:307-319. [PMID: 30063243 PMCID: PMC6322973 DOI: 10.1002/bit.26809] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 07/22/2018] [Accepted: 07/26/2018] [Indexed: 12/28/2022]
Abstract
Newly recognized as natural nanocarriers that deliver biological information between cells, extracellular vesicles (EVs), including exosomes and microvesicles, provide unprecedented therapeutic opportunities. Large-scale and cost-effective manufacturing is imperative for EV products to meet commercial and clinical demands; successful translation requires careful decisions that minimize financial and technological risks. Here, we develop a decision support tool (DST) that computes the most cost-effective technologies for manufacturing EVs at different scales, by examining the costs of goods associated with using published protocols. The DST identifies costs of labor and consumables during EV harvest as key cost drivers, substantiating a need for larger-scale, higher-throughput, and automated technologies for harvesting EVs. Importantly, we highlight a lack of appropriate technologies for meeting clinical demands, and propose a potentially cost-effective solution. This DST can facilitate decision-making very early on in development and be used to predict, and better manage, the risk of process changes when commercializing EV products.
Collapse
Affiliation(s)
- Kelvin S. Ng
- Harvard‐MIT Division of Health Sciences and TechnologyCambridgeMassachusetts
- Division of Engineering in Medicine, Department of MedicineBrigham & Women’s Hospital, Harvard Medical SchoolBostonMA
- Harvard Stem Cell InstituteCambridgeMassachusetts
- RoosterBioFrederickMaryland
| | - James A. Smith
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal SciencesUniversity of OxfordOxfordUK
- The Oxford‐UCL Centre for the Advancement of Sustainable Medical Innovation, University of OxfordOxfordUK
| | - Matthew P. McAteer
- Department of NeurologyMassachusetts General Hospital, Harvard Medical SchoolCharlestownMassachusetts
| | - Benjamin E. Mead
- Harvard‐MIT Division of Health Sciences and TechnologyCambridgeMassachusetts
- Division of Engineering in Medicine, Department of MedicineBrigham & Women’s Hospital, Harvard Medical SchoolBostonMA
- Harvard Stem Cell InstituteCambridgeMassachusetts
- Broad Institute of Harvard and MITCambridgeMassachusetts
- Koch Institute for Integrative Cancer Research, MITCambridgeMassachusetts
| | - Jamie Ware
- The Oxford‐UCL Centre for the Advancement of Sustainable Medical Innovation, University of OxfordOxfordUK
| | - Felix O. Jackson
- The Oxford‐UCL Centre for the Advancement of Sustainable Medical Innovation, University of OxfordOxfordUK
| | - Alison Carter
- Department of PaediatricsUniversity of OxfordOxfordUK
| | - Lino Ferreira
- University of Coimbra, Center for Neuroscience and Cell BiologyPortugal
| | - Kim Bure
- The Oxford‐UCL Centre for the Advancement of Sustainable Medical Innovation, University of OxfordOxfordUK
| | | | - Brock Reeve
- Harvard Stem Cell InstituteCambridgeMassachusetts
| | - David A. Brindley
- Harvard Stem Cell InstituteCambridgeMassachusetts
- The Oxford‐UCL Centre for the Advancement of Sustainable Medical Innovation, University of OxfordOxfordUK
- Department of PaediatricsUniversity of OxfordOxfordUK
- Centre for Behavioural Medicine, UCL School of Pharmacy, University College LondonLondonUK
- UCSF‐Stanford Center of Excellence in Regulatory Science and InnovationSan FranciscoCalifornia
| | - Jeffrey M. Karp
- Harvard‐MIT Division of Health Sciences and TechnologyCambridgeMassachusetts
- Division of Engineering in Medicine, Department of MedicineBrigham & Women’s Hospital, Harvard Medical SchoolBostonMA
- Harvard Stem Cell InstituteCambridgeMassachusetts
- Broad Institute of Harvard and MITCambridgeMassachusetts
| |
Collapse
|
3
|
Montacir O, Montacir H, Springer A, Hinderlich S, Mahboudi F, Saadati A, Parr MK. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept. Protein J 2018; 37:164-179. [DOI: 10.1007/s10930-018-9757-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
4
|
Abstract
Protein glycosylation is post-translational modification (PTM) which is important for pharmacokinetics and immunogenicity of recombinant glycoprotein therapeutics. As a result of variations in monosaccharide composition, glycosidic linkages and glycan branching, glycosylation introduces considerable complexity and heterogeneity to therapeutics. The host cell line used to produce the glycoprotein has a strong influence on the glycosylation because different host systems may express varying repertoire of glycosylation enzymes and transporters that contributes to specificity and heterogeneity in glycosylation profiles. In this review, we discuss the types of host cell lines currently used for recombinant therapeutic production, their glycosylation potential and the resultant impact on glycoprotein properties. In addition, we compare the reported glycosylation profiles of four recombinant glycoproteins: immunoglobulin G (IgG), coagulation factor VII (FVII), erythropoietin (EPO) and alpha-1 antitrypsin (A1AT) produced in different mammalian cells to establish the influence of mammalian host cell lines on glycosylation.
Collapse
Affiliation(s)
- Justin Bryan Goh
- a Bioprocessing Technology Institute , Agency for Science, Technology and Research (A*STAR) , Singapore , Singapore
| | - Say Kong Ng
- a Bioprocessing Technology Institute , Agency for Science, Technology and Research (A*STAR) , Singapore , Singapore
| |
Collapse
|
5
|
Gugliotta A, Ceaglio N, Raud B, Forno G, Mauro L, Kratje R, Oggero M. Glycosylation and antiproliferative activity of hyperglycosylated IFN-α2 potentiate HEK293 cells as biofactories. Eur J Pharm Biopharm 2016; 112:119-131. [PMID: 27867113 DOI: 10.1016/j.ejpb.2016.11.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Revised: 09/22/2016] [Accepted: 11/13/2016] [Indexed: 01/23/2023]
Abstract
Both CHO and HEK cells are interesting hosts for the production of biotherapeutics due to their ability to introduce post-translational modifications such as glycosylation. Even though oligosaccharide structures attached to proteins are conserved among eukaryotes, many differences have been found between therapeutic glycoproteins expressed in hamster and human derived cells. In this work, a hyperglycosylated IFN-α2b mutein (IFN4N) was produced in CHO and HEK cell lines and an extensive characterization of their properties was performed. IFN4NCHO exhibited a higher average molecular mass and more acidic isoforms compared to IFN4NHEK. In agreement with these results, a 2-times higher sialic acid content was found for IFN4NCHO in comparison with the HEK-derived protein. This result was in agreement with monosaccharide quantification and glycan's analysis using WAX chromatography and HILIC coupled to mass spectrometry; all methods supported the existence of highly sialylated and also branched structures for IFN4NCHO glycans, in contrast with smaller and truncated structures among IFN4NHEK glycans. Unexpectedly, those remarkable differences in the glycosylation pattern had not a considerable impact on the clearance rate of both molecules in rats. In fact, although IFN4NHEK reached maximum plasma concentration 3-times faster than IFN4NCHO, their elimination profile did not differ significantly. Also, despite the in vitro antiviral specific biological activity of both proteins was the same, IFN4NHEK was more efficient as an antiproliferative agent in different tumor-derived cell lines. Accordingly, IFN4NHEK showed a higher in vivo antitumor activity in animal models. Our results show the importance of an appropriate host selection to set up a bioprocess and potentiate the use of HEK293 cells for the production of a new hyperglycosylated protein-based pharmaceutical.
Collapse
Affiliation(s)
- Agustina Gugliotta
- UNL, CONICET, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina
| | - Natalia Ceaglio
- UNL, CONICET, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina
| | - Brenda Raud
- UNL, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina
| | - Guillermina Forno
- UNL, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina; Zelltek S.A., PTLC RN 168, (S3000ZAA) Santa Fe, Argentina
| | - Laura Mauro
- Zelltek S.A., PTLC RN 168, (S3000ZAA) Santa Fe, Argentina
| | - Ricardo Kratje
- UNL, CONICET, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina
| | - Marcos Oggero
- UNL, CONICET, FBCB, Cell Culture Laboratory, Ciudad Universitaria UNL.C.C. 242, (S3000ZAA) Santa Fe, Argentina.
| |
Collapse
|
6
|
Jungblut P, Thiede B, Schlüter H. Towards deciphering proteomes via the proteoform, protein speciation, moonlighting and protein code concepts. J Proteomics 2016; 134:1-4. [DOI: 10.1016/j.jprot.2016.01.012] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
7
|
Applying Acylated Fucose Analogues to Metabolic Glycoengineering. Bioengineering (Basel) 2015; 2:213-234. [PMID: 28952479 PMCID: PMC5597091 DOI: 10.3390/bioengineering2040213] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 11/13/2015] [Accepted: 11/23/2015] [Indexed: 11/25/2022] Open
Abstract
Manipulations of cell surface glycosylation or glycan decoration of selected proteins hold immense potential for exploring structure-activity relations or increasing glycoprotein quality. Metabolic glycoengineering describes the strategy where exogenously supplied sugar analogues intercept biosynthetic pathways and are incorporated into glycoconjugates. Low membrane permeability, which so far limited the large-scale adaption of this technology, can be addressed by the introduction of acylated monosaccharides. In this work, we investigated tetra-O-acetylated, -propanoylated and -polyethylene glycol (PEG)ylated fucoses. Concentrations of up to 500 µM had no substantial effects on viability and recombinant glycoprotein production of human embryonic kidney (HEK)-293T cells. Analogues applied to an engineered Chinese hamster ovary (CHO) cell line with blocked fucose de novo synthesis revealed an increase in cell surface and recombinant antibody fucosylation as proved by lectin blotting, mass spectrometry and monosaccharide analysis. Significant fucose incorporation was achieved for tetra-O-acetylated and -propanoylated fucoses already at 20 µM. Sequential fucosylation of the recombinant glycoprotein, achieved by the application of increasing concentrations of PEGylated fucose up to 70 µM, correlated with a reduced antibody’s binding activity in a Fcγ receptor IIIa (FcγRIIIa) binding assay. Our results provide further insights to modulate fucosylation by exploiting the salvage pathway via metabolic glycoengineering.
Collapse
|